Features

Escalating energy and raw materials costs was the number one story in the bio/pharmaceutical industry in 2022, but what other news was noteworthy in deal-making, expansions, and industry performance. DCAT Value Chain Insights provides its Top 10 News Stories of 2022.

Akin to the 505 (B)(2) pathway in the US, Medicines for Europe is calling on EU authorities to recognize value-added medicines as separate group of medicines in EU legislation with new approval procedures, innovation frameworks and reimbursement processes.

Rising energy and raw materials costs are two key factors impacting the chemical manufacturing value chain for intermediates and small-molecule APIs. What other key developments and trends are impacting the fine-chemicals market?

With more than one month remaining in 2022, which of the bio/pharmaceutical majors are leading the pack with blockbusters (defined as products with sales of $1 billion or more)? DCAT Value Chain Insights takes an inside look.

Increased demand in biologic-based drug development is a key factor driving demand for parenteral drug manufacturing. What are key trends and expansions by CDMO/CMOs in parenteral drug manufacturing? DCAT Value Chain Insights rounds up the latest developments among CDMO/CMOs.  

Energy, inflationary pressures, and mitigating supplier risk are high priorities for Bayer. In Germany, the company aims to be independent of Russian gas by the end of the year and says that procurement management and supply chain stability are top priorities.

Although cell & gene therapies are a niche product area, the industry as a whole faces limited capacity. Both large and small CDMOs continue to expand manufacturing capacity for cell and gene therapies. Which companies are in the mix and are expanding?

The FDA is launching a Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot program to facilitate the expedited review of products with accelerated development timeframes.

The European Chemical Industry Council (Cefic) is calling for more action to address Europe’s energy crisis. For the first time ever, the EU is importing more chemicals than it exports, and Cefic is proposing specific measures to address the energy crisis and the adverse impact on chemical production.

A recent study by the management consultancy, EY, showed that a majority of supply-chain executives are focused on environmental, social and governance (ESG) initiatives, but lack capabilities to measure supply-chain sustainability. What can be done?